• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.
【24h】

Otelixizumab: a novel agent for the prevention of type 1 diabetes mellitus.

机译：Otelixizumab：一种预防1型糖尿病的新型药物。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: Type 1 diabetes mellitus is a chronic, progressive autoimmune disorder linked to numerous genetic and environmental factors. Insulin is the only treatment and preventative strategies do not currently exist. An obvious need exists to develop a safe regimen that suppresses the progression of the disease. AREAS COVERED: A MEDLINE search (1966-June 2011) was conducted for English-language articles using the terms 'otelixizumab', 'anti-CD3 antibody' and 'prevention of type 1 diabetes mellitus'. Relevant literature on otelixizumab, an anti-CD3 monoclonal antibody, currently in Phase III clinical trials for prevention of T1DM is discussed. EXPERT OPINION: Studies suggest that a monoclonal antibody directed against CD3 mitigates the deterioration in insulin production and decreases the rise in insulin requirement in recent onset T1DM for up to five years. The benefit was most pronounced in younger patients and in those with higher initial beta-cell function. Adverse effects were significant but transient. Otelixizumab shows great promise but leaves room for improvement. Results of ongoing trials will help define its role in the prevention of T1DM.
机译：简介：1型糖尿病是一种慢性进行性自身免疫性疾病，与许多遗传和环境因素有关。胰岛素是唯一的治疗方法，目前尚无预防策略。显然存在开发抑制疾病进展的安全方案的需求。覆盖的区域：对MEDLINE搜索（1966年-2011年6月），其中使用术语“ otelixizumab”，“抗CD3抗体”和“预防1型糖尿病”来搜索英语文章。讨论了目前正在III期预防T1DM的抗CD3单克隆抗体otelixizumab的相关文献。专家意见：研究表明，针对CD3的单克隆抗体可缓解最近5年内发病的T1DM中胰岛素产生的恶化，并降低胰岛素需求量的上升。这种益处在年轻患者和初始β细胞功能较高的患者中最为明显。不良反应明显，但短暂。奥替昔单抗显示出巨大的希望，但仍有改进的空间。正在进行的试验结果将有助于确定其在预防T1DM中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号